DNA topoisomerases of leishmania: The Potential targets for anti-leishmanial therapy

Advances in Experimental Medicine and Biology

Volumn 625, Issue , 2008, Pages 103-115

  Majumder, Hemanta K ^a   Das, Benu Brata ^b   Ganguly, Agneyo ^b  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOACRIDINE; AMSACRINE; ANTILEISHMANIAL AGENT; ANTIMONY; BAICALEIN; BETULIC ACID; CAMPTOTHECIN; DIHYDROBETULINIC ACID; DIOSPYRIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FOSTRIECIN; INDENOISOQUINOLINE DERIVATIVE; IRINOTECAN; KINETOPLAST DNA; LUTEOLIN; MEGLUMINE ANTIMONATE; MERBARONE; PENTAMIDINE; QUERCETIN; STIBOGLUCONATE SODIUM; SURAMIN; TENIPOSIDE; TOPOTECAN; UNCLASSIFIED DRUG; UREASTIBAMINE;

CELL PROLIFERATION; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME SPECIFICITY; ESCHERICHIA COLI; GENETIC VARIABILITY; LEISHMANIA; LEISHMANIA DONOVANI; LEISHMANIASIS; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SACCHAROMYCES CEREVISIAE; TROPICS; TRYPANOSOMA CRUZI;

EUKARYOTA; KINETOPLASTIDA; PROTOZOA;

EID: 84934442209     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-77570-8_9     Document Type: Review

References (63)

1. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19:111-26.
2. Wang JC. Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol 2002; 6:430-40.
3. Champoux JJ. DNA topoisomerases: Structure, function, and mechanism. Annu Rev Biochem 2001; 70:369-413.
4. Ferguson LR, Baguley BC. Topoisomerase II enzymes and mutagenicity. Environ Mol Mutagen 1994; 24:245-261.
5. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58:351-75.
6. Burri C, Bodley AL, Shapiro TA. Topoisomerases in kinetoplastids. Parasitol Today 1996; 6:226-31.
7. Bjornsti MA, Wang JC. Expression of yeast DNA topoisomerase I can complement a conditional-lethal DNA topoisomerase I mutation in Escherichia coli. Proc Natl Acad Sci USA 1987; 84:8971-8975.
8. Stewart L, Ireton GC, Champoux JJ. Reconstitution of human topoisomerase I by fragment" complementation. J Mol Biol 1997; 269:355-372.
9. Berger JM. Structure of DNA topoisomerases. Biochim Biophys Acta 1998; 1400:3-18.
10. Bakshi RP, Galande S, Muniyappa K. Functional and regulatory characteristics of eukaryotic type II DNA topoisomerases. Crit Rev Biochem Mol Biol 2001; 36:1-37.
11. Wang JC. DNA topoisomerases: Why so many? J Biol Chem 1991; 266:6659-6662.
12. Broxterman HJ, Georgopapadakou N. Cancer research 2001: Drug resistance, new targets and drug combinations. Drug Resist Updat 2001; 4:197-209.
13. Nitiss JL. DNA topoisomerases in cancer chemotherapy: Using enzymes to generate selective DNA damage. Curr Opin Investig Drugs 2002; 3:1512-1516.
14. Denny WA, Baguley BC. Dual Topoisomerase I/II Inhibitors in Cancer Therapy Curr. Top Med Chem 2003; 3:339-353.
15. Shapiro TA. Inhibition of topoisomerases in African trypanosomes. Acta Trop 1993; 54:251-260.
16. Bodley AL, Wani MC, Wall ME et al. Antitrypanosomal activity of camptothecin analogs. Structure- activity correlations. Biochem Pharmacol 1995; 50:937-942.
17. Bearden DT, Danziger LH. Mechanism of action of and resistance to quinolones. Pharmacotherapy 2001; 21:224S-232S.
18. Chakraborty AK, Majumder HK. Mode of action of pentavalent antimonials: Specific inhibition of type I DNA topoisomerase of Leishmania donovani. Biochem Biophys Res Commun 1988; 152:605-611.
19. Chakraborty AK et al. A type I DNA topoisomerase from the kinetoplast hemoflagellate Leishmania donovani. Ind J Biochem Biophys 1993; 30:257-263.
20. Riou GF et al. A type I DNA topoisomerase from Trypanosoma cruzi. Eur J Biochem 1983; 134:479-484.
21. Melendy T, Ray DS. Purification and nuclear localization of type I topoisomerase from Crithidia fasciculata. Mol Biochem Parasitol 1987; 24:215-225.
22. Bodley AL, Shapiro TA. Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania. Proc Natl Acad Sci USA 1995; 92:3726-3730.
23. Broccoli S, Marquis JF, Papadopoulou B et al. Characterization of a Leishmania donovani gene encoding a protein that resembles a type IB topoisomerase. Nucleic Acids Res 1999; 27:2745-52.
24. Champoux JJ. Domains of human topoisomerase I and associated functions. Prog Nucleic Acid Res Mol Biol 1998; 60:111-32.
25. Das A, Dasgupta A, Sengupta T et al. Topoisomerases of kinetoplastid parasites as potential chemotherapeutic targets. Trends Parasitol 2004; 8:381-387.
26. Bodley AL, Shapiro TA. Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania. Proc Nail Acad Sci USA 1995; 92:3726-3730.
27. Villa H, OteroMarcos AR, Reguera RM et al. A novel active DNA topoisomerase I in Leishmania donovani. J Biol Chem 2003; 278:3521-6.
28. Stewart L, Ireton GC, Champoux JJ. The domain organization of human Topoisomerase I. J Biol Chem 1996; 271:7602-8.
29. D'Arpa P, Machlin PS, Ratrie IIIrd H et al. cDNA cloning of human DNA Topoisomerase I: Catalytic activities of a 67.7kDa carboxy-terminal fragment. Proc Natl Acad Sci USA 1988; 85:2543-7.
30. Liu LF, Miller KG. Eukaryotic DNA topoisomerases: Two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc Nail Acad Sci USA 1981; 78:3487-91.
31. Das BB, Sen N, Ganguly A et al. Reconstitution and functional characterization of the unusual bi-subunit type I DNA topoisomerase from Leishmania donovani. FEBS Lett 2004; 565:81-88.
32. Das BB, Sen N, Dasgupta SB et al. N-terminal region of the large subunit of Leishmania donovani bisubunit topoisomerase I is involved in DNA relaxation and interaction with the smaller subunit. J Biol Chem 2005; 280:16335-44.
33. Bakshi RP, Shapiro TA. RNA interference of Trypanosoma brucei topoisomerase IB: Both subunits are essential. Mol Biochem Parasitol 2004; 136:249-55.
34. Davies DR, Mushtaq A, Interthal H et al. The structure of the transition state of the heterodimeric topoisomerase I of Leishmania donovani as a vanadate complex with nicked DNA. J Mol Biol 2006; 357:1202-10.
35. Melendy T, Shelina C, Ray DS. Localization of a type II DNA topoisomerase to two sites at the periphery of the kinetoplast DNA of Crithidia fasciculata. Cell 1988; 55:1083-1088.
36. Das A, Dasgupta A, Sharma S et al. Characterisation of the gene encoding type II DNA topoisomerase from Leishmania donovani: A key molecular target in antileishmanial therapy. Nucleic Acids Res 2001; 29:1844-1851.
37. Gaziova I, Lukes J. Mitochondrial and nuclear localization of topoisomerase II in the flagellate Bodo saltans (Kinetoplastida), a species with noncatenated kinetoplast DNA. J Biol Chem 2003; 278:10900-10907.
38. Lynn R, Giaever G, Swanberg SL et al. Tandem regions of yeast DNA topoisomerase II share homology with different subunits of bacterial gyrase. Science 1986; 233:647-649.
39. Liu LF, Liu CC, Alberts BM. T4 DNA topoisomerase: A new ATP dependent enzyme for T4 bacteriophage DNA replication. Nature 1979; 281:456-461.
40. Seasholtz AF, Greenberg GR. Identification of bacteriophage T4 gene 60 product and a role for this protein in DNA topoisomerase. J Biol Chem 1983; 258:1221-1226.
41. Sengupta T, Mukherjee M, Mandal CN et al. Functional dissection of the C-terminal domain of type II DNA topoisomerase of kinetoplastid hemoflagellate Leishmania donovani. Nucleic Acids Res 2003; 31:5305-5316.
42. Sengupta T, Mukherjee M, Das R et al. characterization of the DNA-binding domain and identification of the active site residue in the gyr A half of Leishmania donovani topoisomerase II. Nucleic Acids Res 2005; 33:2364-73.
43. Sengupta T, Mukherjee M, Das A et al. Characterization of the ATPase activity of topoisomerase II from L. donovani and identification of the residues conferring resistance to etoposide. Biochem J 2005; 390:419-26.
44. Campbell S, Maxwell A. The ATP-operated clamp of human DNA topoisomerase IIalpha: Hyperstimulation of ATPase by "piggy-back" binding. J Mol Biol 2002; 320:171-188.
45. Tsai-Pflugfelder M, Liu LF, Liu AA et al. Cloning and sequencing C- DNA encoding human topoisomerase II and localization of the gene to chromosome region 1988; 17q21-22.
46. Vilian N, Tsai-Pflugfelder M, Benoit A et al. Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase II alpha. Nucleic Acids Res 2003; 31:5714-5722.
47. Wang JC. DNA topoisomerase as targets of therapeutics: An overview. Adv Pharmacol 1994; 29A: 1-9.
48. Chakraborty AK, Majumder HK. Mode of action of pentavalent antimonials: Specific inhibition of type I DNA topoisomerase of Leishmania donovani. Biochem Biophys Res Commun 1988; 152:605-11.
49. Lucumi A, Robledo S, Gama V et al. Sensitivity of Leishmania viannia panamensis to pentavalent antimony is correlated with the formation of cleavable DNA-protein complexes. Antimicrob Agents Chemother 1998; 42:1990-5.
50. Marquis JF, Hardy I, Olivier M. Topoisomerase I amino acid substitutions, Gly185Arg and Asp325Glu, confer camptothecin resistance in Leishmania donovani. Antimicrob Agents Chemother 2005; 49:1441-6.
51. Sen N, Das BB, Ganguly A et al. Camptothecin induced mitochondrial dysfunction leading to programmed cell death in unicellular hemoflagellate Leishmania donovani. Cell Death Differ 2004; 11:924-36.
52. Sen N, Das BB, Ganguly A et al. Camptothecin-induced imbalance in intracellular cation homeostasis regulates programmed cell death in unicellular hemoflagellate Leishmania donovani. J Biol Chem 2004; 279:52366-75.
53. Slunt KM, Grace JM, Macdonald TL et al. Effect of mitonafide analogs on topoisomerase II of Leishmania chagasi. Antimicrob Agents Chemother 1996; 40:706-709.
54. Werbovetz KA, Spoors PG, Pearson RD et al. Cleavable complex formation in Leishmania chagasi treated with anilinoacridines. Mol Biochem Parasitol 1994; 65:1-10.
55. Gamage SA, Figgitt DP, Wojcik SJ et al. Structure-activity relationships for the antileishmanial and antitrypanosomal activities of 1'-substituted 9-anilinoacridines. J Med Chem 1997; 40:2634-42.
56. Werbovetz KA, Lehnert EK, Macdonald TL et al. Cytotoxicity of acridine compounds for Leishmania promastigotes in vitro. Antimicrob Agents Chemother 1992; 36:495-497.
57. Ray S, Majumder HK, Chakravarty AK et al. Amarogentin, a naturally occurring secoiridoid glycoside and a newly recognized inhibitor of topoisomerase I from Leishmania donovani. J Natl Prod 1996; 59:27-29.
58. Medda S, Mukhopadhyay S, Basu MK. Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms. J Antimicrob Chemother 1999; 44:791-4.
59. Ray S, Sadhukhan PK, Mandal NB et al. Dual inhibition of DNA topoisomerases of Leishmania donovani by novel Indolyl quinolines. Biochem Biophys Res Commun 1997; 230:171-175.
60. Ray S, Hazra B, Mittra Bet al. Diospyrin, a bisnaphthoquinone: A novel inhibitor of type I DNA topoisomerase of Leishmania donovani. Mol Pharmacol 1998; 54:994-999.
61. Chowdhury AR, Mandal S, Goswami A et al. Dihydrobetulinic acid induces apoptosis in Leishmania donovani by primarily targeting DNA topoisomerase I and II: Implications in antileishmanial therapy. Mol Med 2003; 9:26-36.
62. Mittra B, Saha H, Chowdhury AR et al. Luteolin, an abundant dietary component is a potent anti-leishmanial agent that acts by inducing topoisomerase II-mediated kinetoplast DNA cleavage leading to apoptosis. Mol Med 2000; 6:527-541.
63. Das BB, Sen N, Roy A et al. Differential induction of Leishmania donovani bi-subunit topoisomerase I-DNA cleavage complex by selected flavones and camptothecin: Activity of flavones against camptothecin-resistant topoisomerase I. Nucleic Acids Res 2006; 34:21-32.